Wenbiao Xian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wenbiao Xian has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Fengjuan Su
Department of Neurology, The First Affiliated Hospital, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Sun Yat-Sen University, Guangzhou, China
5 shared publicationsLishan Lin
Department of Neurology, The First Affiliated Hospital, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Sun Yat-Sen University, Guangzhou, China
5 shared publications- Zhong Pei
Department of Neurology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
5 shared publications Weineng Chen
Department of Neurology, The First Affiliated Hospital, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Sun Yat-Sen University, Guangzhou, China
3 shared publicationsCurtis B. Ashford
MemTrax, LLC, Redwood City, USA
2 shared publicationsFeng Li
Kunming Escher Technology Co. Ltd, Kunming, China
2 shared publications
Latest Publications
- Open Access
- 8 August 2026
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 18 (1)
MemTrax as a scalable digital triage tool for mild cognitive impairment screening: primary validation in Alzheimer’s disease and exploratory analysis in Parkinson’s disease
- 8 August 2026
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 18 (1)
Open AccessMemTrax as a scalable digital triage tool for mild cognitive impairment screening: primary validation in Alzheimer’s disease and exploratory analysis in Parkinson’s disease
- Open Access
- 30 January 2026
- Published by Elsevier in EBioMedicine
- Vol. 124, 106133
Deep learning enhanced ALPS reveals genetic and environmental factors of brain glymphatic function
- 30 January 2026
- Published by Elsevier in EBioMedicine
- Vol. 124, 106133
Open AccessDeep learning enhanced ALPS reveals genetic and environmental factors of brain glymphatic function
- 27 January 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (2) , 101
Real-time detection and subtyping of “On-meds” freezing of gait in Parkinson’s disease using lower-limb acceleration data
- 27 January 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (2) , 101
Real-time detection and subtyping of “On-meds” freezing of gait in Parkinson’s disease using lower-limb acceleration data
- Open Access
- 7 October 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (10) , e70793
Effect of Preinfection Health Status on COVID‐19 Severity and Cognitive Function
Background: This observational cohort study investigates how infection health factors influence COVID‐19 severity and cognitive outcomes. We collected preinfection data from hospitalized COVID‐19 patients, including demographic information and baseline health conditions prior to diagnosis, and examined their associations with hospitalization duration and cognitive function assessed after infection. Methods: Data were obtained from Hui Ya Hospital, The First Affiliated Hospital, Sun Yat‐sen University, China. The study included confirmed COVID‐19 patients requiring hospitalization. Among the 147 collected cases, two were excluded due to missing data, leaving a final sample of 145 patients. The Montreal Cognitive Assessment (MoCA), which evaluates global cognitive function with a total score of 0–30, was used to assess cognitive function, while hospitalization duration and routine clinical examinations were analyzed as indicators of disease severity. Additionally, the SF‐12v2 score reflecting Health‐Related Quality of Life was used to evaluate patients' overall health status. Statistical analyses were conducted to identify preinfection factors associated with COVID‐19 outcomes. Results: Preinfection baseline health status was significantly correlated with both hospitalization duration ( p < 0.0001, 95% CI [−0.47, −0.16]) and MoCA scores ( p = 0.0001, 95% CI [0.15, 0.46]). Patients with better preinfection health conditions experienced shorter hospital stays and demonstrated better cognitive function postinfection. Conclusion: Our findings indicate that preinfection baseline health conditions play a crucial role in determining both the severity of COVID‐19 and postinfection cognitive function. Specifically, impairments were more pronounced in the visuospatial, naming, attention, calculation, language, and memory domains. Additionally, our results suggest a potential link between COVID‐19 outcomes and patients’ preexisting underlying diseases.
- 7 October 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (10) , e70793
Open AccessEffect of Preinfection Health Status on COVID‐19 Severity and Cognitive Function
Background: This observational cohort study investigates how infection health factors influence COVID‐19 severity and cognitive outcomes. We collected preinfection data from hospitalized COVID‐19 patients, including demographic information and baseline health conditions prior to diagnosis, and examined their associations with hospitalization duration and cognitive function assessed after infection. Methods: Data were obtained from Hui Ya Hospital, The First Affiliated Hospital, Sun Yat‐sen University, China. The study included confirmed COVID‐19 patients requiring hospitalization. Among the 147 collected cases, two were excluded due to missing data, leaving a final sample of 145 patients. The Montreal Cognitive Assessment (MoCA), which evaluates global cognitive function with a total score of 0–30, was used to assess cognitive function, while hospitalization duration and routine clinical examinations were analyzed as indicators of disease severity. Additionally, the SF‐12v2 score reflecting Health‐Related Quality of Life was used to evaluate patients' overall health status. Statistical analyses were conducted to identify preinfection factors associated with COVID‐19 outcomes. Results: Preinfection baseline health status was significantly correlated with both hospitalization duration ( p < 0.0001, 95% CI [−0.47, −0.16]) and MoCA scores ( p = 0.0001, 95% CI [0.15, 0.46]). Patients with better preinfection health conditions experienced shorter hospital stays and demonstrated better cognitive function postinfection. Conclusion: Our findings indicate that preinfection baseline health conditions play a crucial role in determining both the severity of COVID‐19 and postinfection cognitive function. Specifically, impairments were more pronounced in the visuospatial, naming, attention, calculation, language, and memory domains. Additionally, our results suggest a potential link between COVID‐19 outcomes and patients’ preexisting underlying diseases.
- Open Access
- 7 February 2024
- Published by Wiley in Brain and Behavior
- Vol. 14 (2)
Fatigue and long duration of infection are associated with worsen motor and non‐motor symptoms in Parkinson's disease following Omicron COVID‐19 pandemic
Background: Coronavirus disease 2019 (COVID‐19) may influence the clinical course and symptoms of chronic neurological diseases, such as Parkinson's disease (PD), which can persist even after recovery from the infection. This longitudinal study aimed at exploring the impact of the COVID‐19 on motor and non‐motor symptoms and the related risk factors for exacerbation of PD symptoms.Methods: One hundred and two PD patients underwent a first assessment between September 2022 and November 2022 (T0) before Omicron COVID‐19 pandemic. They were then contacted again and asked to complete the second assessment between December 2022 and February 2023 (T1) following Omicron infection. Movement Disorders Society Unified PD Rating Scale Part III, Non‐Motor Symptoms Scale, Fatigue Severity Scale (FSS), and quality of life were investigated.Results: Ninety‐five PD patients (93.1%) with COVID‐19 for the first time were mild cases. However, 55 patients (55.9%) experienced worsening motor symptoms of PD after recovering from the infectious symptoms. Preinfection FSS score (odds ratios [OR] 2.062, 95% confidence interval [CI] 1.081–3.933, p = .028) and duration of infection (OR 1.232, 95% CI 1.024–1.481, p = .027) were independent risk factors for the worsening of motor symptoms. PD patients with post‐COVID‐19 fatigue were more likely to experience worsened non‐motor symptoms, resulting in an impaired quality of life.Conclusion: This study confirms the impact of the Omicron COVID‐19 pandemic on the motor and non‐motor symptoms of PD, suggesting that management of related factors, including fatigue and duration of infection, may be beneficial in preventing or dealing with the exacerbation of PD symptoms after infection.
- 7 February 2024
- Published by Wiley in Brain and Behavior
- Vol. 14 (2)
Open AccessFatigue and long duration of infection are associated with worsen motor and non‐motor symptoms in Parkinson's disease following Omicron COVID‐19 pandemic
Background: Coronavirus disease 2019 (COVID‐19) may influence the clinical course and symptoms of chronic neurological diseases, such as Parkinson's disease (PD), which can persist even after recovery from the infection. This longitudinal study aimed at exploring the impact of the COVID‐19 on motor and non‐motor symptoms and the related risk factors for exacerbation of PD symptoms.Methods: One hundred and two PD patients underwent a first assessment between September 2022 and November 2022 (T0) before Omicron COVID‐19 pandemic. They were then contacted again and asked to complete the second assessment between December 2022 and February 2023 (T1) following Omicron infection. Movement Disorders Society Unified PD Rating Scale Part III, Non‐Motor Symptoms Scale, Fatigue Severity Scale (FSS), and quality of life were investigated.Results: Ninety‐five PD patients (93.1%) with COVID‐19 for the first time were mild cases. However, 55 patients (55.9%) experienced worsening motor symptoms of PD after recovering from the infectious symptoms. Preinfection FSS score (odds ratios [OR] 2.062, 95% confidence interval [CI] 1.081–3.933, p = .028) and duration of infection (OR 1.232, 95% CI 1.024–1.481, p = .027) were independent risk factors for the worsening of motor symptoms. PD patients with post‐COVID‐19 fatigue were more likely to experience worsened non‐motor symptoms, resulting in an impaired quality of life.Conclusion: This study confirms the impact of the Omicron COVID‐19 pandemic on the motor and non‐motor symptoms of PD, suggesting that management of related factors, including fatigue and duration of infection, may be beneficial in preventing or dealing with the exacerbation of PD symptoms after infection.
- 1 February 2024
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 120, 106016
The MemTrax memory test for detecting and assessing cognitive impairment in Parkinson's disease
- 1 February 2024
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 120, 106016
The MemTrax memory test for detecting and assessing cognitive impairment in Parkinson's disease
- 3 January 2024
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 170, 107959
Parkinson's severity diagnosis explainable model based on 3D multi-head attention residual network
- 3 January 2024
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 170, 107959
Parkinson's severity diagnosis explainable model based on 3D multi-head attention residual network
- Open Access
- 29 November 2022
- Published by Hindawi Limited in Parkinson's Disease
- Vol. 2022, 1-12
Nomogram for Prediction of Postoperative Delirium after Deep Brain Stimulation of Subthalamic Nucleus in Parkinson’s Disease under General Anesthesia
Introduction. Postoperative delirium can increase cognitive impairment and mortality in patients with Parkinson’s disease. The purpose of this study was to develop and internally validate a clinical prediction model of delirium after deep brain stimulation of the subthalamic nucleus in Parkinson’s disease under general anesthesia. Methods. We conducted a retrospective observational cohort study on the data of 240 patients with Parkinson’s disease who underwent deep brain stimulation of the subthalamic nucleus under general anesthesia. Demographic characteristics, clinical evaluation, imaging data, laboratory data, and surgical anesthesia information were collected. Multivariate logistic regression was used to develop the prediction model for postoperative delirium. Results. A total of 159 patients were included in the cohort, of which 38 (23.90%) had postoperative delirium. Smoking (OR 4.51, 95% CI 1.56–13.02, ) was the most important risk factor; other independent predictors were orthostatic hypotension (OR 3.42, 95% CI 0.90–13.06, ), inhibitors of type-B monoamine oxidase (OR 3.07, 95% CI 1.17–8.04, ), preoperative MRI with silent brain ischemia or infarction (OR 2.36, 95% CI 0.90–6.14, ), Hamilton anxiety scale score (OR 2.12, 95% CI 1.28–3.50, ), and apolipoprotein E level in plasma (OR 1.48, 95% CI 0.95–2.29, ). The area under the receiver operating characteristic curve (AUC) was 0.76 (95% CI 0.66–0.86). A nomogram was established and showed good calibration and clinical predictive capacity. After bootstrap for internal verification, the AUC was 0.74 (95% CI 0.66–0.83). Conclusion. This study provides evidence for the independent inducing factors of delirium after deep brain stimulation of the subthalamic nucleus in Parkinson’s disease under general anesthesia. By predicting the development of delirium, our model may identify high-risk groups that can benefit from early or preventive intervention.
- 29 November 2022
- Published by Hindawi Limited in Parkinson's Disease
- Vol. 2022, 1-12
Open AccessNomogram for Prediction of Postoperative Delirium after Deep Brain Stimulation of Subthalamic Nucleus in Parkinson’s Disease under General Anesthesia
Introduction. Postoperative delirium can increase cognitive impairment and mortality in patients with Parkinson’s disease. The purpose of this study was to develop and internally validate a clinical prediction model of delirium after deep brain stimulation of the subthalamic nucleus in Parkinson’s disease under general anesthesia. Methods. We conducted a retrospective observational cohort study on the data of 240 patients with Parkinson’s disease who underwent deep brain stimulation of the subthalamic nucleus under general anesthesia. Demographic characteristics, clinical evaluation, imaging data, laboratory data, and surgical anesthesia information were collected. Multivariate logistic regression was used to develop the prediction model for postoperative delirium. Results. A total of 159 patients were included in the cohort, of which 38 (23.90%) had postoperative delirium. Smoking (OR 4.51, 95% CI 1.56–13.02, ) was the most important risk factor; other independent predictors were orthostatic hypotension (OR 3.42, 95% CI 0.90–13.06, ), inhibitors of type-B monoamine oxidase (OR 3.07, 95% CI 1.17–8.04, ), preoperative MRI with silent brain ischemia or infarction (OR 2.36, 95% CI 0.90–6.14, ), Hamilton anxiety scale score (OR 2.12, 95% CI 1.28–3.50, ), and apolipoprotein E level in plasma (OR 1.48, 95% CI 0.95–2.29, ). The area under the receiver operating characteristic curve (AUC) was 0.76 (95% CI 0.66–0.86). A nomogram was established and showed good calibration and clinical predictive capacity. After bootstrap for internal verification, the AUC was 0.74 (95% CI 0.66–0.83). Conclusion. This study provides evidence for the independent inducing factors of delirium after deep brain stimulation of the subthalamic nucleus in Parkinson’s disease under general anesthesia. By predicting the development of delirium, our model may identify high-risk groups that can benefit from early or preventive intervention.
- Open Access
- 1 September 2020
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 21 (1) , 1-8
Muscular involvement and tendon contracture in limb-girdle muscular dystrophy 2Y: a mild adult phenotype and literature review
Background: Limb girdle muscular dystrophy type 2Y (LGMD2Y) is a rare subgroup of limb girdle muscular dystrophy featuring limb-girdle weakness, tendon contracture and cardiac involvement. It is caused by the mutation of TOR1AIP1, which encodes nuclear membrane protein LAP1 (lamina-associated polypeptide 1) and comprises heterogeneous phenotypes. The present study reported a patient with a novel homozygous TOR1AIP1 mutation that presented with selective muscle weakness, which further expanded the phenotype of LGMD2Y- and TOR1AIP1-associated nuclear envelopathies. Case presentation: A 40-year-old male presented with Achilles tendon contracture and muscle weakness that bothered him from 8 years old. While the strength of his distal and proximal upper limbs was severely impaired, the function of his lower limbs was relatively spared. Muscle pathology showed dystrophic features, and electron microscopy showed ultrastructural abnormalities of disrupted muscle nuclei envelopes. Whole-exome sequencing showed a frameshift mutation in TOR1AIP1 (c.98dupC). Conclusion: We reported a novel mild phenotype of LGMD2Y with relatively selective distal upper limb weakness and joint contracture and revealed the heterogeneity of LGDM2Y and the role of the LAP1 isoform by literature review.
- 1 September 2020
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 21 (1) , 1-8
Open AccessMuscular involvement and tendon contracture in limb-girdle muscular dystrophy 2Y: a mild adult phenotype and literature review
Background: Limb girdle muscular dystrophy type 2Y (LGMD2Y) is a rare subgroup of limb girdle muscular dystrophy featuring limb-girdle weakness, tendon contracture and cardiac involvement. It is caused by the mutation of TOR1AIP1, which encodes nuclear membrane protein LAP1 (lamina-associated polypeptide 1) and comprises heterogeneous phenotypes. The present study reported a patient with a novel homozygous TOR1AIP1 mutation that presented with selective muscle weakness, which further expanded the phenotype of LGMD2Y- and TOR1AIP1-associated nuclear envelopathies. Case presentation: A 40-year-old male presented with Achilles tendon contracture and muscle weakness that bothered him from 8 years old. While the strength of his distal and proximal upper limbs was severely impaired, the function of his lower limbs was relatively spared. Muscle pathology showed dystrophic features, and electron microscopy showed ultrastructural abnormalities of disrupted muscle nuclei envelopes. Whole-exome sequencing showed a frameshift mutation in TOR1AIP1 (c.98dupC). Conclusion: We reported a novel mild phenotype of LGMD2Y with relatively selective distal upper limb weakness and joint contracture and revealed the heterogeneity of LGDM2Y and the role of the LAP1 isoform by literature review.